Table 3.
NT‐proBNP, MR‐proANP, Copeptin, and MR‐proADM Reactions in Both Randomized Groups
| Baseline | 95% CI | 30 Minutes After Induction | 95% CI | P time×randomization | |
|---|---|---|---|---|---|
| NT‐proBNPint fv (pg/mL) n=29 | 63.9 | 45.1 to 90.5 | 66 | 46.5 to 93.8 | 0.073 |
| NT‐proBNPcon fv (pg/mL) n=16 | 97.5 | 61.1 to 155.7 | 97.7 | 61.5 to 155.2 | |
| NT‐proBNPint CS (pg/mL) n=26 | 82 | 58.1 to 115.7 | 92.7 | 69.4 to 123.9 | 0.882 |
| NT‐proBNPcon CS (pg/mL) n=13 | 144.4 | 87 to 239.8 | 158.2 | 93.5 to 268 | |
| NT‐proBNPint LA (pg/mL) n=29 | 61.4 | 43 to 87.5 | 65.3 | 46.2 to 92.3 | <0.001a |
| NT‐proBNPcon LA (pg/mL) n=16 | 94.3 | 59 to 150.8 | 92.9 | 58.8 to 146.9 | |
| MR‐proANPint fv (pmol/L) n=29 | 98.4 | 82.8 to 113.9 | 152 | 125.7 to 183.8 | <0.001a |
| MR‐proANPcon fv (pmol/L) n=16 | 102.7 | 77.9 to 151.3 | 108.3 | 85.2 to 137.8 | |
| MR‐proANPint CS (pmol/L) n=26 | 132.5 | 105.9 to 165.9 | 234.2 | 197.7 to 277.4 | <0.001a |
| MR‐proANPcon CS (pmol/L) n=13 | 151.5 | 116.1 to 197.8 | 161.7 | 123.2 to 213.6 | |
| MR‐proANPint LA (pmol/L) n=29 | 95.7 | 79.2 to 115.5 | 165.5 | 136.6 to 200.5 | <0.001a |
| MR‐proANPcon LA (pmol/L) n=16 | 100.9 | 79.5 to 128.1 | 106.2 | 82.7 to 136.4 | |
| Copeptinint fv (pmol/L) n=29 | 8.21 | 5.5 to 12.27 | 6.53 | 4.36 to 9.78 | 0.245 |
| Copeptincon fv (pmol/L) n=16 | 6.68 | 4.95 to 9.01 | 6.92 | 4.86 to 9.84 | |
| Copeptinint CS (pmol/L) n=26 | 9.05 | 5.86 to 14 | 6.77 | 4.39 to 10.46 | 0.225 |
| Copeptincon CS (pmol/L) n=13 | 7.19 | 5.38 to 9.62 | 7.13 | 4.78 to 10.63 | |
| Copeptinint LA (pmol/L) n=29 | 8.03 | 5.33 to 12.1 | 6.33 | 4.23 to 9.48 | 0.202 |
| Copeptincon LA (pmol/L) n=16 | 6.71 | 4.85 to 9.28 | 6.44 | 4.23 to 9.46 | |
| MR‐proADMint fv (nmol/L) n=29 | 0.583 | 0.53 to 0.636 | 0.568 | 0.522 to 0.614 | 0.363 |
| MR‐proADMcon fv (nmol/L) n=16 | 0.654 | 0.565 to 0.734 | 0.655 | 0.562 to 0.747 | |
| MR‐proADMint CS (nmol/L) n=26 | 0.563 | 0.513 to 0.613 | 0.558 | 0.507 to 0.61 | 0.61 |
| MR‐proADMcon CS (nmol/L) n=13 | 0.636 | 0.547 to 0.724 | 0.628 | 0.528 to 0.728 | |
| MR‐proADMint LA (nmol/L) n=29 | 0.544 | 0.495 to 0.593 | 0.537 | 0.492 to 0.582 | 0.037 |
| MR‐proADMcon LA (nmol/L) n=16 | 0.577 | 0.508 to 0.645 | 0.605 | 0.538 to 0.673 |
NT‐proBNP, MR‐proANP, and copeptin levels are presented as geometric means with 95% CI; MR‐proADM levels are presented as means with 95% CI. Results from repeated‐measure ANOVA within‐subjects contrast tests are presented after correction for false discovery rates due to multiple testing. ANOVA indicates analysis of variance; CI, confidence interval; con, control group; CS, coronary sinus; fv, femoral vein; int, intervention group; LA, left atrium; MR‐proADM, midregional portion of proadrenomedullin; MR‐proANP, midregional fragment of the N‐terminal precursor of atrial natriuretic peptide; n, number of patients available for analysis; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide.
Statistical significant P values after correction for false discovery rate.